Publications by authors named "Lisa Liverman"

Claim this Profile
A
Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.
Douglas J Biedenbach, David J Farrell, Robert K Flamm, Lisa C Liverman, Gail McIntyre

Int J Antimicrob Agents· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, double-blind, phase II, multicenter study evaluating the safety/tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infection.
Paul Covington, J Michael Davenport, David Andrae, William O'Riordan, Lisa Liverman

Antimicrob Agents Chemother· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surveillance of JNJ-Q2 activity tested against Staphylococcus aureus and beta-hemolytic streptococci as a component of the 2010 SENTRY Antimicrobial Surveillance Program.
David J Farrell, Lisa C Liverman, Douglas J Biedenbach, Robert K Flamm, Ronald N Jones

Diagn Microbiol Infect Dis· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determination of disk diffusion and MIC quality control guidelines for JNJ-Q2, a novel quinolone.
James E Ross, Lisa C Liverman, Ronald N Jones

J Clin Microbiol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains.
David J Farrell, Lisa C Liverman, Douglas J Biedenbach, Ronald N Jones

Antimicrob Agents Chemother· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis